<DOC>
	<DOCNO>NCT01563068</DOCNO>
	<brief_summary>Calcipotriene vitamin D3 analog use topical therapy adult subject plaque-type psoriasis since 1993 . Calcipotriene foam , 0.005 % , approved 2010 treatment plaque psoriasis adult age 18 year old . The current study multicenter study adolescent subject ( age 12 16 year , inclusive ) primary caregiver apply calcipotriene foam , 0.005 % , thin layer treatment area body scalp , exclude face , maximal use condition , twice day 14 day Day 15 . The safety , tolerability , pharmacodynamics , pharmacokinetics calcipotriene evaluate</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability , Pharmacodynamics Pharmacokinetics Calcipotriene 0.005 % , Applied Under Maximal Use Conditions 12-16 Year Olds With Plaque Psoriasis</brief_title>
	<detailed_description>This Phase 1 multicenter , open-label , repeat-dose study design evaluate safety , tolerability , pharmacodynamics , pharmacokinetics calcipotriene foam , 0.005 % , apply topically adolescent subject moderate plaque psoriasis ( define score 3 Investigator 's Static Global Assessment [ ISGA ] ) involve minimum 10 % body surface area ( BSA ) exclude face scalp , minimum 20 % scalp involvement . Subjects enrol 2 week Screening . Approximately 30 eligible subject , age 12 16 year , inclusive , enrolled ensure 20 complete subject . Calcipotriene foam apply thin layer twice day 14 day Day 15 treatment area . Blood sample evaluation albumin adjust calcium , intact parathyroid hormone ( iPTH ) , alkaline phosphatase , magnesium , phosphorus take Screening Day 1 ( first dose ) , Day 15 ( 3 9 hour dose ) , Day 22 result Day 15 show abnormality . Serum 25-OH vitamin D concentration evaluate Day 1 ( first dose ) . Safety tolerability evaluate throughout treatment period 7 day follow-up period . Blood sample pharmacokinetic ( PK ) evaluation collect Days 1 15 . Urine sample evaluation calcium/creatinine ratio collect dosing Days 1 15 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Male female subject , age 12 16 year , inclusive , time consent . 2 . Plaque psoriasis involve 10 % body surface area ( exclude scalp face ) . 3 . 20 % scalp involvement ( exclude body face ) . 4 . Clinical diagnosis mild moderate plaque psoriasis , define ISGA score Screening 3 scale 0 4 . 5 . The ability willingness subject subject 's primary caregiver follow study procedure , attend schedule visit , successfully complete study . 5 . The subject 's parent ( ) legal guardian must ability understand sign write informed consent form Health Insurance Portability Accountability Act ( HIPAA ) authorization form , must obtain prior participation study . The HIPAA authorization may incorporate informed consent form . Also , subject 's assent must obtain document . 1 . Any inflammatory skin disease treatment area may confound evaluation plaque psoriasis ( eg , atopic dermatitis , contact dermatitis , tinea corporis ) . 2 . Current diagnosis unstable form psoriasis treatment area , include guttate , erythrodermic , exfoliative , pustular psoriasis . 3 . Use topical product ( include sunscreen , cream , ointment , lotion , powder ) apply near treatment area within 48 hour prior enrollment . 4 . Use topical treatment know beneficial effect psoriasis , include limited corticosteroid , retinoids , vitamin D derivative , coal tar , tazarotene , anthralin , medicate shampoo within 2 week prior enrollment . 5 . Use nonbiologic systemic antipsoriatic therapy ( eg , corticosteroid , retinoids , methotrexate , cyclosporine , immunosuppressive agent ) , biologic therapy ( eg , alefacept , etanercept , efalizumab ) , phototherapy ( eg , ultraviolet A , psoralen ultraviolet A , ultraviolet B ) within 4 week prior enrollment . 6 . Use need initiation nonpsoriatic therapy might affect psoriasis ( include antimalarial , adrenergic receptor blocker , interferon , lithium ) within 4 week prior enrollment . 7 . Use medication affect change calcium parathyroid hormone ( PTH ) concentration interfere measurement calcium PTH concentration within 4 week prior enrollment . 8 . Known difficult venous access beyond expect subject age . 9 . Any serious skin disorder chronic medical condition well control . 10 . Positive urine drug screen result alcohol , cotinine , drug abuse time Screening . 11 . Average daily ingestion 2000 mg elemental calcium 1000 IU vitamin D within 2 week prior enrollment . 12 . Current drug alcohol abuse . 13 . History hypersensitivity , know allergy , adverse reaction calcipotriene vitamin D analog component study product . 14 . Current past history hypercalcemia , vitamin D toxicity , severe renal insufficiency , severe hepatic disorder . 15 . Use investigational therapy within 4 week prior enrollment . 16 . Pregnant , breastfeeding , sexually active female subject childbearing potential ( menarche ) practice acceptable method contraception . Acceptable method contraception include one follow highly effective method contraception ( ie , Pearl Index &lt; 1.0 % ) : complete abstinence intercourse 2 form barrier contraception ( diaphragm plus spermicide female , condom plus spermicide male ) , systemic contraceptive ( combine progesterone ) use combination condom . The subject must agree use acceptable method contraception 2 week prior administration study product , throughout study , 28 day completion premature discontinuation study . 17 . Current immunosuppression . 18 . Albuminadjusted serum calcium Screening outside normal reference range . 19 . Any condition , judgment investigator , would put subject unacceptable risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>plaque psoriasis</keyword>
</DOC>